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1. Introduction 
The interest of clinicians and researchers concerning the quality of life (QoL) assessment in 
chronic diseases increases constantly. Many definitions have been proposed for the term 
quality of life, but it is commonly accepted that a universal definition of QoL is rather 
infeasible to be given. Furthermore, Aaronson has noted the multidimensionality of QoL in 
terms of physical (symptoms of a disease and treatment), functional (activities of daily 
living, mobility), social (interpersonal contacts and relationships) and psychological (mental 
health, emotional balance) parameters that compose it.1 
Since the first research efforts that tried to examine QoL in glaucoma2, serious advancement 
has been accomplished in this field, offering a better understanding of how and to what 
extend glaucoma influences QoL of individuals suffering from the disease. In addition, 
glaucoma QoL research yielded important insights with regard to the domains of daily 
living that are mostly affected by the disease.  
It is well documented that glaucoma is a leading cause of visual impairment and blindness. 
Epidemiologic studies demonstrate that 2% of adults over the age of 40 suffer from 
glaucoma, with the disease prevalence increasing significantly with age.3,4 Vision loss exerts 
a negative impact on physical ability of patients to perform activities of daily living 
(reading, adapting to different levels of light, outdoor mobility, avoiding obstacles, etc.), 
despite maintenance of central visual acuity in less advanced stages of the disease.5 
Furthermore, literature suggests that patients with impaired QoL form a more severe 
burden on health-care resources.6,7  
Knowledge and information regarding the QoL of glaucoma patients could be useful in 
several aspects. It can help ‘decision making’ concerning customized disease management of 
individuals with glaucoma and promote alterations and guidelines regarding patients’ daily 
living and safety (i.e. adjustment of home environment), in order to avoid problems 
concerning adaptation to variable lighting conditions, avoiding obstacles, near activities, 
outdoor mobility/activities (walking, driving) and other tasks that glaucoma patients seem 
to give the greatest importance and are significantly correlated with their QoL.8,29 The 
diagnosis of glaucoma impacts individuals differently, with the majority of cases having 
little understanding of the need for adherence to their daily therapeutic regimen and the 
disease natural course and progress.9 Towards this direction, information gained from QoL 
studies could improve the education of newly diagnosed patients and help them realize the 
severity of the disease and the importance of the adherence to daily treatment, despite the 
fact that symptoms are absent in early stages.  
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Deterioration of quality of life due to glaucoma can occur because of many reasons. The 
diagnosis itself, the progressive visual field loss, the intolerance of daily treatment, the side 
effects of topical anti-glaucoma medication (i.e. allergic conjunctivitis, dry eye, blepharitis), 
the constrictions concerning daily activities and the need of intensive and long-lasting 
observation and monitoring on an outpatient basis are some of these causes. In addition 
QoL is a more subjective rather than objective assessment,10 since individuals with common 
visual deterioration due to glaucoma may estimate their QoL state differently. It is then 
obvious why QoL is considered to be subjective and multidimensional,1 and why its 
assessment and the extent of the impact that glaucoma exerts on it is difficult to be 
accomplished and evaluated.  
In general, QoL can be estimated by means of a series of instruments-questionnaires. In 
specific, generic health-related [the Short Form Health Survey-36 (SF-36), the Sickness 
impact Profile (SIP)], vision-specific (VS) [ the Visual Function-14 (VF-14), the National Eye 
Institute Visual Function Questionnaire-25 (NEIVFQ-25)] and glaucoma-specific [the 
Glaucoma Symptom Scale (GSS), the Glaucoma Quality of Life-15 (GQL-15)] QoL 
instruments (Table 1) have been employed to better rate glaucoma’s impact on patients’ 
daily living and enlighten clinicians about how patients experience the effect of glaucoma in 
their quality of life. 
2. Validation of QoL instruments 
Proper validation of a questionnaire’s basic psychometric properties is considered a 
prerequisite (before it is administrated to subjects and implemented to studies), in order its’ 
efficacy to be established. Psychometric properties indicate the quality status of an 
instrument and can be assessed by the classic test theory and/or by Rasch analysis. Both 
methods provide significant information about item selection, subscale structure and 
interpretability of an instrument. 
The basic psychometric properties that are based on classic test theory are the ‘content 
validity’ and the ‘internal consistency’, the ‘construct validity’, the ‘reproducibility’ and the 
‘respondent burden’ of an instrument. 
‘Content validity’ evaluates if the items of the questionnaire measure the basic parameter 
(i.e. QoL) that is purported to measure and is necessary during the development of the  
tool.11 It consists from 3 phases: item collection phase, item reduction phase and segregation 
of items in subscales phase that is accomplished by factor analysis or principal component 
analysis. ‘Internal consistency’ assesses the affinity of both the questionnaires’ items and 
subscales. It is measured by calculation of the Cronbach α value. Cronbach α should range 
between 0.70-0.90.12  
‘Construct validity’ expresses the associations of an instrument with other measurements or 
questionnaires (i.e. visual field (VF) scores, visual acuity). No specific measurement or value 
evaluates construct validity. 
‘Reproducibility’ evaluates the extent to which the instrument’s scores have limited 
fluctuations after repetition (test-retest reproducibility) or between observers (inter-observer 
reproducibility). The intraclass correlation coefficient (ICC) and the Bland-Altman analysis 
are the most common measures of reproducibility.12-14 
‘Respondent burden’ demonstrates the questionnaire’s demands from the respondents (i.e. 
time needed to respond to the instrument, emotional burden placed on respondents, the 
ratio of missing items). Andresen suggested that 15 min is the maximum temporal limit of a 
questionnaire’s completion regarding disabled people.15 
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QoL Instruments Features 
Generic Health-related  
SF-36 
36 items, 8 subscales: general health, mental health, physical 
functions, social functions,  
role limitations by physical/mental disability, vitality and pain 
MOS-20 
Shorter version of SF-36. 20 items, 6 subscales: physical 
functioning, social functioning,  
role functioning, mental health, health perceptions, pain 
SIP 
136 items, 12 subscales, implemented by CIGTS after 
modification 
Vision-Specific  
VF-14 
14 items/vision-related activities, originally designed to 
evaluate functional impairment in cataract patients  
ADVS 
20 items, 5 subscales: distance vision, near vision, day driving, 
night driving and glare, originally designed to evaluate 
functional impairment in cataract patients 
NEI-VFQ 
51 items, 12 subscales; NEI-VFQ 25: 25 items, 12 domains, 
shorter and more practical  
tool from NEI-VFQ  
IVI 
32 items, 5 subscales: leisure and work, consumer and social 
interaction, household and personal care, mobility and 
emotional reaction to vision loss 
VAQ 
30 items, 8 subscales: acuity/spatial vision, peripheral vision, 
visual search, visual  
processing speed, color discrimination, glare disability, 
light/dark adaptation and depth perception. 
Glaucoma-Specific  
GSS 10 items, 2 subscales: (non-visual) symptom and visual ability  
GQL-15 
15 (glaucoma-specific) items demonstrating significant 
association with visual field loss 
SIG 
43 items, 4 subscales: visual ability, local eye, systemic and 
psychological, developed for  
the CIGTS 
GHPI 
6 items addressing the ‘physical’, ‘emotional’, ‘social’ and the 
‘stress’ and ‘worry of blindness associated with glaucoma’ 
effects on QoL, developed for the CIGTS 
 
Table 1. Prevalent QoL questionnaires used in glaucoma-related studies 
On the other hand, Rasch analysis provides interval ratings regarding the items’ difficulty 
(item measures), the response choices (of an item) (response measures) and the persons’ 
ability (person measures),16 usually by means of fit (infit/outfit) meansquare (MNSQ) 
statistics.17 Fit statistics calculate errors in the item, response and person measures that can 
occur because of redundancy or inappropriate construction during item and response 
choices selection. MNSQ values between 0.7 and 1.3 are considered acceptable. Items or 
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response choices with MNSQ values outside these limits are considered misfitting and 
should be rephrased or omitted during the instrument’s development.18 When items ‘fit’ the 
model, then the instrument measures the underlying trait (i.e QoL). 
In addition, another basic component of Rasch analysis is the ‘person separation’ measure. 
‘Person separation’ measures the ability of an instrument to distinguish subgroups of 
individuals (or items).19 The higher the (person separation) reliability coefficient, the more 
subgroups can be discriminated. In order a questionnaire to be considered acceptable the 
reliability coefficient should be at least 0.8 (it is able to discriminate 3 groups).19  
3. Generic health-related instruments  
Health-related tools try by nature to estimate the overall quality of life of subjects, without 
taking into account separate coexisting diseases or assessing how they individually impact 
QoL. It is rather difficult to attribute possible decreased QoL scores recorded by general 
health-related instruments only to glaucoma, without taking into account other co-
morbidities that may also affect results. Thus, it is not surprising that general health-related 
tools lack sensitivity in the glaucoma QoL assessment domain. 
3.1 The medical outcomes study (MOS-20) and the short form-36 (SF-36) 
The SF-36 questionnaire contains 36 questions that are divided into eight subscales.20 It has 
been used widely and administrated to patients with different diseases, it is suitable for  
self-administration and is considered reliable.21 The MOS-20 composes a shorter form of the 
SF-36.22 
The administration to glaucoma patients showed ambiguous results. A study found that 
glaucoma patients provided the lowest scores among three groups (glaucoma patients, 
glaucoma suspects and healthy subjects),23 while another study indicated similar SF-36 
scores between glaucoma and normal individuals. Furthermore, glaucoma seemed to 
greater affect vitality, mental health, bodily pain and social functioning domains.2,24 
Nevertheless, correlations between SF-36 subscales and visual acuity or visual field 
impairment have been found relative week, and therefore it is considered unsuitable for the 
QoL assessment in glaucoma.2,25 Glaucoma subjects presented significantly lower scores 
than healthy individuals in all MOS-20 subscales except pain.26 General health, physical and 
role functioning MOS-20 domains demonstrated the most significant differences between 
the two groups (-22%, -20% and -43%, respectively).26 
3.2 The sickness impact profile (SIP) 
The SIP questionnaire was initially developed in order to provide a measurable instrument 
of general health status that would be able to record the impact of different disease states. It 
includes 136 items categorized in 12 domains and showed good test-retest reliability and 
internal consistency. It takes more than 30 minutes to complete, is not user friendly and is 
unsuitable for implementation in daily clinical practice.27 
The SIP instrument was employed by the Collaborative Initial Glaucoma Treatment Study 
(CIGTS) and after modification it was administrated to newly diagnosed glaucoma patients. 
Although showing good psychometric properties, the correlations between QoL 
measurements and clinical parameters were found weak but significant. In addition, 
glaucoma exerted a slightly stronger impact on the patients’ psychological domain than the 
physical one.28-30 
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4. Vision specific instruments 
Vision specific tools belong to the category of QoL instruments that try to directly link the 
quality of life status of individuals with a certain human function. These questionnaires 
have been commonly administered to ophthalmic patients, trying to assess the QoL status in 
a wide range of ocular diseases, including glaucoma. 
4.1 The visual function-14 (VF-14) 
The VF-14 was constructed to assess vision-specific functional activities in cataract patients. 
It consists of 14 vision-related activity questions.31 Studies suggest that VF-14 has good 
internal consistency and that VF-14 scores correlate with visual acuity stronger than health-
related instruments.32 
After administration to glaucoma patients, the VF-14 showed moderate correlation with 
visual field loss and visual acuity.2,40 However VF-14 proved incapable to distinguish 
normal from glaucoma subjects (P=0.07)40 In another publication, glaucoma patients 
presented worse weighted mean VF-14 scores than cataract subjects but better than AMD 
patients.33 Furthermore, it doesn’t assess colour vision and other significant factors 
indicating optic nerve damage, making it inappropriate for QoL rating in glaucoma and in 
optic neuropathies in general. 
4.2 The activities of daily vision scale (ADVS) 
The ADVS includes 20 items categorized in the following subscales: near vision, far vision, 
day and night vision/driving, glare and overall vision. It is a cataract-oriented tool with 
good psychometric properties and is easy to use.34 
ADVS was able to discriminate glaucoma patients from healthy subjects and ADVS scores 
showed significant correlation with visual acuity and visual field scores in patients with 
glaucoma.26 Furthermore, individuals with bilateral glaucoma reported more difficulty (3 
times greater probability) on the ADVS than normal subjects, while more advanced 
binocular VF impairment was correlated with a greater probability of selecting the most 
difficulty (response scale) on the instrument.35 Patients with unilateral glaucoma in the 
study demonstrated an average mean defect VF index (MD) in the worse eye of -6.5 dB, 
while the average MD for the bilateral glaucoma group was -12.0 dB. The study could not 
elucidate whether the greater perceived difficulty found was due to bilaterality or greater 
VF loss.35 However the questionnaire doesn’t evaluate the parameter of peripheral field and 
therefore is less relative to glaucoma patients.  
4.3 The national eye institute visual function questionnaire -51 (NEI-VFQ) and -25 
(NEI-VFQ 25) 
The NEI-VFQ and NEI-VFQ 25 instruments are used as benchmarks in the vision-related 
QoL evaluation and many disease-specific tools are compared with them in order their 
efficacy to be established. The NEI-VFQ is a fully validated, 51 item, 12-domain tool that has 
been widely used in several ocular morbidities. The NEI-VFQ 25 is a 25 item, 12 domain 
instrument that is a shorter and more practical version of its predecessor, designed mainly 
for clinical settings, with its validity proven to be similar with that of the NEI-VFQ.36,37 
Studies agree that the domains affected greater in glaucoma subjects are mainly general 
health, general vision, mental health, expectations, driving and near activities both for NEI-
VFQ and NEI-VFQ 25 questionnaires.2,24,33,38-39 Both tools are shown to be capable of 
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distinguishing glaucoma from normal control subjects, with the scores of glaucoma patients 
being significantly poorer on most subscales. In addition, lower scores correlated well with 
visual field loss of glaucoma patients in the eye with the least visual field deterioration.40  
4.4 The impact of vision impairment (IVI)  
The IVI questionnaire is a vision-specific QoL instrument that consists of 32 queries divided 
in 5 subscales: leisure and work, consumer and social interaction, household and personal 
care, mobility, and emotional reaction to vision loss.41 
After administration to patients with glaucoma or age related macular degeneration (AMD), 
responses from glaucoma patients were greater (indicating more difficulty to a certain 
domain) in most subscales, including emotional reaction to vision loss, leisure, mobility, 
household and social interaction domains. 41 Only the social interaction subscale score was 
found greater for AMD subjects (indicating more difficulty in this domain).41 When it was 
administered only to glaucoma subjects, responses to the subscale ‘mobility’ were the most 
limited and were proved to correlate significantly with binocular (Esterman) visual field 
deterioration.42  
4.5 The visual activities questionnaire (VAQ) 
The VAQ instrument consists of 33 items that assess the difficulty of individuals in 
performing common visual activities. A 1-5 rating score for each item is used regarding the 
frequency of each visual-related problem. A score of 1 indicates ‘never’, whereas 5 indicates 
‘always’. It provides a total score and VAQ items are further organized in 8 subscales: 
acuity/spatial vision, peripheral vision, visual search, visual processing speed, color 
discrimination, glare disability, light/dark adaptation and depth perception.43 
Concerning glaucoma, the instrument was also employed by the CIGTS demonstrating good 
psychometric features.28 The total VAQ and subscale scores, correlated weakly but 
significantly with visual acuity and VF scores of the better eye.28,30 Particularly the 
peripheral vision subscale showed the strongest correlations with clinical measures (i.e. VA, 
MD, CIGTS scores).28,30 The instrument was found to associate less strongly with glaucoma-
related clinical measures than the NEI-VFQ.44 
5. Glaucoma specific instruments  
Glaucoma specific tools belong to the disease specific QoL instruments category. It has been 
demonstrated that they perform a better discriminating ability between glaucoma and 
normal subjects (specificity for glaucoma). Most of these instruments evaluate both 
symptoms that are relevant to glaucoma and instillation of anti-glaucoma medications (i.e. 
blurry/dim vision, difficulty in seeing in daylight, halos around lights, itching, dryness, 
tearing) and difficulty in performing daily activities.  
5.1 The glaucoma symptom scale (GSS) 
It includes 10 items, grouped into 2 domains: the non-visual symptoms (six items) and the 
visual ability (four items) subscales.45 The instrument was found to demonstrate a good 
internal consistency (Cronbach α> 0.70 for both domains), while GSS visual ability subscale 
showed good correlations with many NEI-VFQ subscales.45 Furthermore, it is short and easy 
to use and thus, very practical for implementing in daily clinical practice. 
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Both GSS subscale responses were rated lower for glaucoma patients, when compared with 
normal control individuals. The GSS visual ability domain served as a better discriminator 
between glaucoma and non-glaucoma subjects.45 However, GSS scores did not demonstrate 
significant correlation with Esterman (binocular) visual field alterations and visual acuity 
was found to associate only moderately with few GSS scores.42,45 Furthermore, the 
instrument excludes treatment related effects on QoL assessment. 
5.2 The glaucoma quality of life-15 (GQL-15) 
GQL-15 was constructed after administration of 50 questions to 47 glaucoma patients who 
were divided into three groups according to the degree of their visual field loss (mild (n = 18), 
moderate (n = 19), and severe visual field loss (n = 10)) and 19 normal controls.46  
Fifteen questions demonstrated significant association with vision field loss and finally were 
included in the GQL questionnaire. 46 Six questions were relevant to glare, six questions 
were relevant to peripheral vision, two questions were relevant to the central-near vision, 
and finally one question was associated with the outdoor mobility. All three glaucoma 
groups exhibited significantly lower scores compared with the normal control group. 
However, glaucoma subjects with moderate and severe visual field deterioration had similar 
responses to the instrument.46 GQL-15 showed excellent validation features (Internal 
consistency: Cronbach alpha = 0.95, test-retest reliability: r = 0.87), while significant 
correlations were found between GQL-15 responses and a number of psychophysical 
measurements: Esterman (binocular) visual field (r = -0.39), dark adaptation (r = 0.34), 
perimetric mean deviation (MD) values (r = -0.6), Pelli-Robson contrast sensitivity (r = -0.45, 
P < 0.001), glare disability (r = -0.41, P < 0.001) and stereopsis (r = 0.26, P = 0.04).46 
Increasing disease severity led to a poorer QoL status, as demonstrated by means of the 
instrument.56 Central and near vision, peripheral vision, and outdoor mobility were the 
most affected domains among individuals with glaucoma.56  
5.3 The symptom impact glaucoma score (SIG) and glaucoma health perceptions 
index (GHPI) 
Both instruments were designed and developed for the Collaborative Initial Glaucoma 
Treatment Study (CIGTS). The SIG consists of 43 queries that are categorized into four 
subscales: visual ability, local eye, systemic and psychological domains. The GHPI contains 
6 queries that try to explore the impact of glaucoma on emotional, physical and social 
aspects of QoL. In addition, the items of GHPI address the stress and worry about blindness 
domains that are in association with living with glaucoma.28  
Both instruments exhibited good internal consistency and reproducibility (Cronbach α and 
ICC > 0.70).28 
After administration to glaucoma subjects, both the SIG visual function subscale and the GHPI 
associated significantly with visual field scores of the worse eye. However the coefficients of 
correlation were found poor (r = 0.136 and 0.165, respectively).28,30 These instruments are 
efficient tools for research settings but seem to have a limited role in clinical practice, since a 
10-hour training course was necessary before being administered to individuals. 
6. Measures of visual function and activities of daily living in glaucoma 
QoL studies suggest tasks requiring central/near vision (i.e. reading), outdoor mobility and 
driving as the most deteriorated activities of daily living among glaucoma subjects.9,49,56 
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Furthermore, the presence of bilateral glaucoma and worse VF impairment seem to be the 
most significant predictors of functional ability regarding glaucoma individuals.48  
Regarding central/near vision activities such as reading, in the Salisbury Eye Evaluation 
(SEE) bilateral glaucoma was associated strongly with reporting the most difficulty on the 
near vision subscale of the ADVS tool (odds ratio 4.57), while the presence of unilateral 
glaucoma was not correlated with any ADVS subscales.35 Furthermore, other relative 
studies regarding glaucoma patients have revealed an association between Esterman 
binocular VF deterioration and both difficulty of finding the next line or following a line in a 
text and reading speed.50,51 
With regard to outdoor mobility, glaucoma patients demonstrated slower walking speed 
when compared with age-matched non-glaucoma subjects, whereas walking speed was 
found to correlate significantly with MD in the worse eye.52 In addition visually impaired 
glaucoma patients were found more prone to accidents and falls compared to glaucoma 
subjects without severe VF loss (odds ratio: 1.6)6, whereas glaucoma subjects presented a 2-4 
time greater probability of falling compared to normal control subjects.53,54 
Concerning driving limitations, glaucoma patients tend to self-report more difficulties in 
driving, while this self reported difficulty correlates with deteriorating VF scores.2,40 The 
SEE study demonstrated that patients with bilateral glaucoma had significantly poorer 
scores on the night driving subscale of ADVS compared to patients with unilateral 
glaucoma and normal control subjects.35 Subjects with bilateral glaucoma were also more 
likely to report the most difficulty on the night driving subscale (odds ratio: 4.19).35 In the 
same study the association between binocular VF and night driving subscale was found 
marginal, while VA and contrast sensitivity (which is a measure that surely deteriorates by 
glaucoma) were associated strongly with lower scores on the aforementioned subscale.35  
Most of the aforementioned results are in accordance with analogous literature reports 
using other QoL assessment instruments such as the NEI-VFQ and NEI-VFQ-25 
questionnaires.40,55 Furthermore, there are a series of studies confirming the negative impact 
of visual field deterioration expressed by means of scores such as MD, pattern standard 
deviation (PSD), Advanced Glaucoma Intervention Study (AGIS) and CIGTS on the total 
QoL status of individuals with glaucoma.30,39,46,57-62 These findings are further supported by 
the presence of the correlation between QoL and VF scores even among individuals who 
were unaware of having glaucoma.62 
7. Conclusion 
QoL is a multidimensional, subjective and dynamic sense. An effort to capture the patients’ 
perceptions and feelings regarding their QoL is difficult to accomplish only by means of an 
artificial construct (i.e QoL questionnaires) and that is because no one can fully comprehend 
exactly how an individual perceives his own QoL state and eventually how he feels.  
An ideal glaucoma QoL assessment tool should be multidimensional (comprise physical, 
social and mental components), enable self-administration, demonstrate good psychometric 
properties and include items that are directly correlated with glaucoma-related clinical 
measurements and are more glaucoma-specific (i.e. GQL-15). In addition, it should be in 
state to discriminate glaucoma patients from healthy individuals and provide responses that 
correlate sufficiently with clinical parameters related to the disease (visual acuity, VF scores, 
contrast sensitivity).  
A great variety of instruments has been administered to glaucoma patients in order to 
evaluate their QoL. All of them have advantages and constraints. Generic health-related 
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tools are useful to make comparisons of QoL in a wide disease spectrum (ocular or not), but 
their generic character limits their specificity for glaucoma. Nevertheless, vision-specific 
tools enable comparisons between glaucoma and other ocular diseases, whereas they are 
more able to distinguish glaucoma patients from normal subjects and correlate better with 
clinical parameters than generic tools.32 Furthermore, they have been used more frequently 
in glaucoma than other QoL instruments. The NEI-VFQ and NEI-VFQ 25 remain the 
benchmark in the vision-related QoL evaluation, with the domains of ‘general health’, 
‘expectations’, ‘mental health’, ‘near activities’ and ‘driving’ being the most affected by 
glaucoma.33 Glaucoma-specific tools are usually composed of items regarding (glaucoma-
related) symptoms and activities of daily living that are more likely to be affected by the 
disease. Furthermore, they try to evaluate the importance that the patients place to their 
QoL deterioration because of the disease.47 Although having specificity for glaucoma and 
correlating strongly with clinical measurements, they do not enable comparisons between 
QoL in glaucoma and other ophthalmic diseases.  
 Research of QoL in glaucoma in recent years has demonstrated significant progress and has 
provided important insights regarding how and to what extend glaucoma impacts on 
patients’ daily living. Studies suggest that glaucoma patients with bilateral VF deterioration 
demonstrate worse performances in activities of daily living, especially in the domains of 
mobility and driving.48 In a literature review that tried to compare QoL in glaucoma and 
other ocular morbidities, glaucoma proved to exert a stronger impact on mental aspects of 
QoL rather than physical ones.33 The authors suggested the asymptomatic (in early stages) 
nature of the disease as a possible explanation. Glaucoma unlike other ophthalmic diseases 
respects the central visual acuity and therefore the ability of individuals suffering from the 
disease to perform certain physical activities could be maintained to a greater extent. Finally 
they concluded that the insufficient education of glaucoma patients regarding their disease 
combined with their worry of possible blindness may lead to a further deterioration of 
mental QoL.33  
There is no ideal glaucoma QoL instrument, mainly due to the complexity and subjectivity 
of QoL. Further research efforts are needed that will address the weaknesses of QoL tools 
with regard to their construction and analysis of the data that are acquired.  
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